Global Protein Therapeutics Market Analysis

Table of Contents

1. Analyst View

2. Global Therapeutic Proteins Market

• 2.1 Market Analysis
  • 2.1.1 Market Size
  • 2.1.2 Therapeutic Proteins Market vs Pharmaceutical Market
  • 2.1.3 Market Segmentation
  • 2.1.4 Future Outlook (2007-2010)

3. Industry Performance

• 3.1 Monoclonal Antibodies (mAb)
  • 3.1.1 Market Size
  • 3.1.2 By Application
    • 3.1.2.1 Oncology Treatment
    • 3.1.2.2 Immunologic & Inflammatory Diseases Treatment
    • 3.1.2.3 Cardiovascular & Infectious Diseases Treatment
  • 3.1.3 Key Geographical Markets
    • 3.1.3.1 US
    • 3.1.3.2 Europe
    • 3.1.3.3 Japan
  • 3.1.4 Key Players & Drugs
  • 3.1.5 Industry Analysis
    • 3.1.5.1 Drivers
    • 3.1.5.2 Restraints
  • 3.1.6 Future Outlook (2007-2011)
• 3.2 Erythropoietin (EPO)
  • 3.2.1 Market Size
    • 3.2.1.1 First Generation Erythropoietin
    • 3.2.1.2 Second Generation Erythropoietin
  • 3.2.2 By Application
    • 3.2.2.1 Renal Anemia Treatment
    • 3.2.2.2 Cancer Anemia Treatment
  • 3.2.3 Key Geographical Markets
    • 3.2.3.1 US
    • 3.2.3.2 Europe
    • 3.2.3.3 Japan
  • 3.2.4 Key Players & Drugs
    • 3.2.4.1 Erythropoietin Alpha
    • 3.2.4.2 Erythropoietin Beta
    • 3.2.4.3 Darbepoetin Alpha
  • 3.2.5 Industry Analysis
    • 3.2.5.1 Drivers
    • 3.2.5.2 Restraints
  • 3.2.6 Future Outlook (2007-2010)
• 3.3 Insulin
  • 3.3.1 Market Size
  • 3.3.2 By Application
    • 3.3.2.1 Diabetes Treatment
  • 3.3.3 Key Geographical Markets
    • 3.3.3.1 India
    • 3.3.3.2 China
    • 3.3.3.3 US
    • 3.3.3.4 Russia
    • 3.3.3.5 Japan
    • 3.3.3.6 Germany
    • 3.3.3.7 Brazil
  • 3.3.4 Key Players & Drugs
  • 3.3.5 Industry Analysis
    • 3.3.5.1 Drivers
    • 3.3.5.2 Restraints
• 3.3.6 Future Outlook (2007-2010)
• 3.4 Interferon (IFN)
  • 3.4.1 Market Size
    • 3.4.1.1 Interferon Alpha
      • 3.4.1.1.1 By Application
        • 3.4.1.1.1.1 Hepatitis B Treatment
        • 3.4.1.1.1.2 Hepatitis C Treatment
    • 3.4.1.2 Interferon Beta
      • 3.4.1.2.1 By Application
        • 3.4.1.2.1.1 Multiple Sclerosis Treatment
  • 3.4.2 Key Geographical Markets
    • 3.4.2.1 US
    • 3.4.2.2 Europe
      • 3.4.2.2.1 Germany
    • 3.4.2.3 Japan
  • 3.4.3 Key Players & Drugs
    • 3.4.3.1 Interferon Alpha
    • 3.4.3.2 Interferon Beta
  • 3.4.4 Industry Analysis
    • 3.4.4.1 Drivers
    • 3.4.4.2 Restraints
• 3.4.5 Future Outlook (2007-2011)
• 3.5 Human Growth Hormone (HGH)
  • 3.5.1 Market Size
  • 3.5.2 By Application
    • 3.5.2.1 Pediatric Growth Hormone Deficiency Treatment
    • 3.5.2.2 Adult Growth Hormone Deficiency Treatment
  • 3.5.3 Key Geographical Markets
    • 3.5.3.1 US
    • 3.5.3.2 Europe & Japan
  • 3.5.4 Key Players & Drugs
  • 3.5.5 Industry Analysis
    • 3.5.5.1 Drivers
    • 3.5.5.2 Restraints
• 3.5.6 Future Outlook (2007-2010)
• 3.6 Blood Clotting Factor
  • 3.6.1 Market Size
    • 3.6.1.1 Recombinant Factor VIII
    • 3.6.1.2 Recombinant Factor VIIa
    • 3.6.1.3 Recombinant Factor IX
  • 3.6.2 Key Players & Drugs
  • 3.6.3 Industry Analysis
    • 3.6.3.1 Drivers
    • 3.6.3.2 Restraints
  • 3.6.4 Future Outlook (2007-2010)
• 3.7 Follicle Stimulating Hormone (FSH)
  • 3.7.1 Market Size
  • 3.7.2 Key Players & Drugs
  • 3.7.3 Industry Analysis
    • 3.7.3.1 Drivers
    • 3.7.3.2 Restraints
  • 3.7.4 Future Outlook (2007-2010)
• 3.8 Granulocyte Colony Stimulating Factor (G-CSF)
  • 3.8.1 Market Size
  • 3.8.2 Key Players & Drugs
  • 3.8.3 Industry Analysis
    • 3.8.3.1 Drivers
    • 3.8.3.2 Restraints
  • 3.8.4 Future Outlook (2007-2010)

4. Industry Analysis

• 4.1 Drivers
  • 4.1.1 Higher Efficacy than Traditional Drugs
  • 4.1.2 High Rate of Approval
  • 4.1.3 Ageing Population
  • 4.1.4 Healthcare Insurance
• 4.2 Opportunities
  • 4.2.1 Biogenerics
  • 4.2.2 Contract Research
  • 4.2.3 Drug Delivery Devices
  • 4.2.4 Healthcare Insurance
  • 4.2.5 Drug Packaging
• 4.3 Challenges
  • 4.3.1 Immunogenicity
  • 4.3.2 High R&D Cost
  • 4.3.3 High Price
  • 4.3.4 High Failure Rates in Phase-3 Clinical Trials
  • 4.3.5 Insurance Reimbursements
  • 4.3.6 Lack of Predictability in the Operating Environment

5. Key Players

• 5.1 Johnson & Johnson
• 5.2 Biogen Idec Inc.
• 5.3 Eli Lilly & Company
• 5.4 Novo Nordisk A/S
• 5.5 Sanofi-Aventis
• 5.6 Roche Group
• 5.7 Amgen Inc.
• 5.8 Genentech, Inc.
• 5.9 Merck Serono S.A
• 5.10 Genzyme Corporation

List of Figures:

• Figure 2-1: Global - Therapeutic Proteins Market (in Billion US$), 2005 & 2006E
• Figure 2-2: Global - Comparison of Therapeutic Proteins Market to Pharmaceutical Market (in Billion US$), 2005 & 2006
• Figure 2-3: Global - Therapeutic Proteins Market by Segment (%), 2006
• Figure 2-4: Global - Forecast for Therapeutic Proteins Market (in Billion US$), 2007-2010
• Figure 2-5: Global - Forecast for Therapeutic Proteins Market by Segment (%), 2010
• Figure 3-1: Global - Monoclonal Antibodies Market (in Billion US$), 2004-2006E
• Figure 3-2: Global - Monoclonal Antibodies Market in Cancer Treatment (in Billion US$), 2001, 2003 & 2006E
• Figure 3-3: Global - Monoclonal Antibodies Market in Rheumatoid Arthritis Treatment (in Million US$), 2003-2005
• Figure 3-4: Global - Monoclonal Antibodies Market in Cardiovascular & Infectious Diseases Treatment (in Million US$), 2004
• Figure 3-5: US - Monoclonal Antibodies Market (in Billion US$), 2005 & 2006E
• Figure 3-6: US - Forecast for Monoclonal Antibodies Market (in Billion US$), 2007-2012
• Figure 3-7: Europe - Monoclonal Antibodies Market (in Billion US$), 2004-2006E
• Figure 3-8: Europe - Forecast for Monoclonal Antibodies Market (in Billion US$), 2007-2011
• Figure 3-9: Europe - Forecast for Monoclonal Antibodies Market by Application (%), 2011
• Figure 3-10: Japan - Monoclonal Antibodies Market (in Billion JPY), 2003-2006E
• Figure 3-11: Japan - Forecast for Monoclonal Antibodies Market (in Billion JPY), 2007-2011
• Figure 3-12: Global - Share of Key Players in Monoclonal Antibodies Market (%), 2005
• Figure 3-13: Global - Top Selling Monoclonal Antibodies (in Million US$), 2006
• Figure 3-14: Global - Number of New Cancer Cases (in Million), 2000 & 2020F
• Figure 3-15: Global - Forecast for Monoclonal Antibodies Market (in Billion US$), 2007-2011
• Figure 3-16: Global - Forecast for Monoclonal Antibodies Market by Application (%), 2011
• Figure 3-17: Global - Erythropoietin Market (in Billion US$), 2005 & 2006
• Figure 3-18: Global - First Generation Erythropoietin Market (in Million US$), 2005 & 2006
• Figure 3-19: Global - First Generation Erythropoietin Alpha Market (in Million US$), 2005 & 2006
• Figure 3-20: Global - First Generation Erythropoietin Beta Market (in Million US$), 2005 & 2006
• Figure 3-21: Global - Second Generation Erythropoietin Market (in Million US$), 2005 & 2006
• Figure 3-22: Global - Number of Dialysis Patients (in Million), 2003-2006E
• Figure 3-23: Global - Breakup of Dialysis Patients by Region (%), 2004
• Figure 3-24: Europe - Number of Dialysis Patients Treated & Not Treated by Erythropoietin (in ‘000), 2004
• Figure 3-25: Europe - Erythropoietin & Untapped Erythropoietin Market (in Million Euro), 2004
• Figure 3-26: Global - Number of Cancer Patients (in Million), 2003-2006E
• Figure 3-27: Global - Breakup of Cancer Patients by Region (%), 2004
• Figure 3-28: Europe - Breakup of Cancer Therapy (%), 2004
• Figure 3-29: Europe - Number of Chemotherapy Patients Treated & Not Treated by Erythropoietin (in ‘000), 2004
• Figure 3-30: Europe - Erythropoietin & Untapped Erythropoietin Market (in Million Euro), 2004
• Figure 3-31: US - Share in Global Erythropoietin Market (%), 2005
• Figure 3-32: Europe - Erythropoietin Market (in Billion US$), 2003-2006E
• Figure 3-33: Europe - Forecast for Erythropoietin Market (in Billion US$), 2007-2011
• Figure 3-34: Europe - Erythropoietin Market in Renal Anemia Treatment (in Million US$), 2004-2006E
• Figure 3-35: Europe - Forecast for Erythropoietin Market in Renal Anemia Treatment (in Million US$), 2007-2011
• Figure 3-36: Europe - Erythropoietin Market in Oncology Treatment (in Million US$), 2004-2006E
• Figure 3-37: Europe - Forecast for Erythropoietin Market in Oncology Treatment (in Million US$), 2007-2011
• Figure 3-38: Europe - First Generation Erythropoietin Patent* Expiry by Major Country
• Figure 3-39: Japan - Erythropoietin Market (in Billion JPY), 2003-2006E
• Figure 3-40: Global - Forecast for Erythropoietin Market (in Billion US$), 2007-2010
• Figure 3-41: Europe - Forecast for Share of Oncology & Renal Anemia in Erythropoietin Market (%), 2016
• Figure 3-42: Global - Insulin Market (in Billion US$), 2005 & 2006
• Figure 3-43: India - Insulin Market (in Million US$), 2004-2007E
• Figure 3-44: India - Share of Key Players in Insulin Market (%), 2004
• Figure 3-45: China - Insulin Market (in Million US$), 2006-2009E
• Figure 3-46: China - Share of Key Players in Insulin Market (%), 2005
• Figure 3-47: US - Insulin Market (in Billion US$), 2002-2006E
• Figure 3-48: US - Share of Key Players in Insulin Market (%), 2005
• Figure 3-49: Russia - Insulin Market (in Million US$), 2005-2008E
• Figure 3-50: Russia - Share of Key Players in Insulin Market (%), 2005
• Figure 3-51: Russia - Insulin Market by Channel of Sales (%), 2005
• Figure 3-52: Japan - Insulin Market (in Million US$), 2005-2008E
• Figure 3-53: Japan - Share of Key Players in Insulin Market (%), 2006
• Figure 3-54: Germany - Share of Insulin in Genetically Manufactured Pharmaceuticals Market (%), 2005
• Figure 3-55: Brazil - Insulin Market (in Million US$), 2000, 2006 & 2010F
• Figure 3-56: Global - Share of Key Players in Insulin Market (%), Q1 2005
• Figure 3-57: Global - Share of Novo Nordisk in Major Insulin Markets (%), 2006
• Figure 3-58: Global - Share of Insulin Market by Brand (%), 2006*
• Figure 3-59: Global - Number of Diabetic Patients (in Million), 2006 & 2025F
• Figure 3-60: Global - Forecast for Insulin Market (in Billion US$), 2007-2010
• Figure 3-61: Global - Interferon Market (in Billion US$), 2005 & 2006
• Figure 3-62: Global - Share of Interferon Market by Segment (%), 2006
• Figure 3-63: Global - Interferon Alpha Market (in Billion US$), 2005 & 2006
• Figure 3-64: Global - Forecast for Hepatitis B Treatment Market (in Billion US$), 2010-2015
• Figure 3-65: Global - Hepatitis C Treatment Market (in Billion US$), 2005 & 2006
• Figure 3-66: Global - Forecast for Hepatitis C Treatment Market (in Billion US$), 2007-2015
• Figure 3-67: Global - Forecast for Share of Interferon in Hepatitis C Treatment Market (%), 2015
• Figure 3-68: Global - Interferon Beta Market (in Billion US$), 2005 & 2006
• Figure 3-69: Global - Multiple Sclerosis Treatment Market (in Billion US$), 2006 & 2016F
• Figure 3-70: US - Interferon Market (in Billion US$), 2006*
• Figure 3-71: Europe - Interferon Market (in Million US$), 2004
• Figure 3-72: Germany - Interferon Market (in Million Euro), 2005
• Figure 3-73: Japan - Interferon Market (in Billion JPY), 2004-2006E
• Figure 3-74: Global - Forecast for Interferon Market (in Billion US$), 2007-2011
• Figure 3-75: Global - Human Growth Hormone Market (in Billion US$), 2005 & 2006
• Figure 3-76: US, Europe & Japan - Number of Patients with Pediatric Growth Hormone Deficiency (in ‘000), 2005
• Figure 3-77: Global - Share of Growth Hormones in Treatment of Pediatric Short Stature (%), 2006
• Figure 3-78: Global - Adult Growth Hormone Deficiency Market (in Million US$), 2006
• Figure 3-79: Global - Breakup of Human Growth Hormone Market by Region (%), 2003
• Figure 3-80: US - Human Growth Hormone Market (in Million US$), 2003, 2005E & 2006E
• Figure 3-81: Japan & Europe - Human Growth Hormone Market (in Million US$), 2003
• Figure 3-82: Global - Share of Key Players in Human Growth Hormone Market (%), 2006
• Figure 3-83: Global - Forecast for Human Growth Hormone Market (in Billion US$), 2007-2010
• Figure 3-84: Global - Blood Clotting Factor Market (in Billion US$), 2005 & 2006
• Figure 3-85: Global - Share of Blood Clotting Factor Market by Segment (%), 2006
• Figure 3-86: Global - Share of Key Players in Blood Clotting Factor Market (%), 2006
• Figure 3-87: Global - Forecast for Blood Clotting Factor Market (in Billion US$), 2007-2010
• Figure 3-88: Global - Recombinant Follicle Stimulating Hormone Market (in Billion US$), 2005 & 2006
• Figure 3-89: Global - Forecast for Recombinant Follicle Stimulating Hormone Market (in Billion US$), 2007-2010
• Figure 3-90: Global - Granulocyte Colony Stimulating Factor Market (in Billion US$), June 2005 & June 2006
• Figure 3-91: Global - Breakup of Granulocyte Colony Stimulating Factor Market by Region (%), 2006
• Figure 3-92: Global - Share of Granulocyte Colony Stimulating Factor Market by Brand (%), 2006*
• Figure 3-93: Global - Forecast for Granulocyte Colony Stimulating Factor Market (in Billion US$), 2007-2010
• Figure 4-1: Global - Approval Rate for Biopharmaceuticals & Conventional Pharmaceuticals (%)
• Figure 4-2: Global - Population in Age Group of 65 Years & Above by Region (%), 2000, 2015F & 2030F
• Figure 4-3: US & EU - Forecast for Biogeneric Market by Segment (in Million US$), 2010
• Figure 4-4: Global - Contract Research Organization Market (in Billion US$), 2006 & 2010F
• Figure 4-5: Global - Forecast for Drug Delivery Market (in Billion US$), 2007-2009
• Figure 4-6: US - Number of Uninsured People (in Million), 2005 & 2006E
• Figure 4-7: Global - Comparison of Annual Cost of Biotech Drugs to Traditional Drugs (in US$), 2006
• Figure 4-8: Global - Failure Rate in Phase-3 Clinical Trials of Biotech & Traditional Drugs (%)

List of Tables:

• Table 3-1: Global - Key Players & Drugs in Erythropoietin Alpha Market by Sale (in Million US$), 2006
• Table 3-2: Global - Key Players & Drugs in Erythropoietin Beta Market by Sale (in Million CHF), 2006
• Table 3-3: Global - Key Players & Drugs in Darbepoetin Alpha Market by Sale (in Million US$), 2006
• Table 3-4: India - Diabetic Patients in Age Group 20-79 (in ‘000), 2003
• Table 3-5: India - Forecast for Diabetic Patients in Age Group 20-79 (in ‘000), 2025
• Table 3-6: China - Diabetic Patients in Age Group 20-79 (in ‘000), 2003
• Table 3-7: China - Forecast for Diabetic Patients in Age Group 20-79 (in ‘000), 2025
• Table 3-8: US - Diabetic Patients in Age Group 20-79 (in ' 000), 2003
• Table 3-9: US - Forecast for Diabetic Patients in Age Group 20-79 (in ‘000), 2025
• Table 3-10: Russia - Diabetic Patients in Age Group 20-79 (in ' 000), 2003
• Table 3-11: Russia - Forecast for Diabetic Patients in Age Group 20-79 (in ' 000), 2025
• Table 3-12: Japan - Diabetic Patients in Age Group 20-79 (in ' 000), 2003
• Table 3-13: Japan - Forecast for Diabetic Patients in 20-79 Age Group (in ' 000), 2025
• Table 3-14: Germany - Diabetic Patients in Age Group 20-79 (in ' 000), 2003
• Table 3-15: Germany - Forecast for Diabetic Patients in Age Group 20-79 (in ' 000), 2025
• Table 3-16: Brazil - Diabetic Patients in Age Group 20-79 (in ' 000), 2003
• Table 3-17: Brazil - Forecast for Diabetic Patients in Age Group 20-79 (in ' 000), 2025
• Table 3-18: Global - Key Players & Drugs in Interferon Alpha Market by Sale (in Million US$), 2006
• Table 3-19: Global - Key Players & Drugs in Interferon Beta Market by Sale (in Million US$), 2006
• Table 3-20: Global - Key Players & Drugs in Human Growth Hormone Market by Sale (in Million US$), 2006
• Table 3-21: Global - Key Players & Drugs in Blood Clotting Factor Market by Sale (in Million US$), 2006
• Table 3-22: Global - Key Players & Drugs in Recombinant Follicle Stimulating Hormone Market by Sale (in Million US$), 2006
• Table 4-1: US & Europe - Patent Expiry Dates for Recombinant Biologics
• Table 5-1: Johnson & Johnson - Key Financials (in Million US$), 2004-2006
• Table 5-2: Biogen Idec Inc. - Key Financials (in Million US$), 2004-2006
• Table 5-3: Eli Lilly & Company - Key Financials (in Million US$), 2004-2006
• Table 5-4: Novo Nordisk A/S - Key Financials (in Million US$), 2004-2006
• Table 5-5: Sanofi-Aventis - Key Financials (in Million US$), 2004-2006
• Table 5-6: Roche Group - Key Financials (in Million CHF), 2004-2006
• Table 5-7: Amgen, Inc. - Key Financials (in Million US$), 2004-2006
• Table 5-8: Genentech, Inc. - Key Financials (in Million US$), 2004-2006
• Table 5-9: Merck Serono S.A - Key Financials (in Million US$), 2003-2005
• Table 5-10: Genzyme Corporation - Key Financials (in Million US$), 2004-2006